Wednesday June 19, 2024

7:00 am Coffee & Check-In

7:55 am Chairs Opening Remarks

8:00 am Roundtable Discussion – Why Have Drugs Failed Within This Space & How Can We Use These Failures to Propel Current Programs Forward?

  • Dinesh Chandra Associate Director, Interventional Oncology, Johnson & Johnson


  • Discussing the fine balance between safety and efficacy with innate immune targeted therapies
  • Actionable insights from reflecting on clinical failures – unpicking lessons learnt
  • Uncovering future directions for those who have experienced clinical setbacks in the space

Leveraging Lessons From The Clinic to Produce Actionable Insights For Future STING/ TLR Agonist Success

9:00 am Therapeutic Modulation of the STING Pathway

9:30 am Morning Break & Speed Networking


The ideal opportunity to get face-to-face with many of the brightest minds working in the STING / TLR field and introduce yourself to the attendees that you would like to have more in-depth conversations with.

Delving Into Clinical Updates From the Landscape of Innate Immune Targeted Therapies

10:30 am An Overview of the Current Development, Clinical Trials & Key Players in the STING & TLR Landscape


  • Providing a comprehensive analysis of STING & TLR-targeting trials and therapies
  • Reviewing STING & TLR-targeting development in the context of the current IO R&D landscape
  • Sharing insights into the rapidly evolving STING & TLR pipeline, combination approaches and future trends

11:00 am Next Generation STING Based Therapeutics in Oncology: Current Progress & Opportunities

  • Dinesh Chandra Associate Director, Interventional Oncology, Johnson & Johnson


  • Evaluate the mechanism of STING based immunotherapies in tumor microenvironments
  • Review the current landscape and challenges in developing STING based immunotherapies
  • Explore the next generation STING based cancer immunotherapies with emerging innovations 

Utilizing Advances in Knowledge to Facilitate Effective Patient Stratification & Clinical Translation

11:30 am Understanding Natural Selection of Common Human STING Alleles in Modern Humans To Advance Precision Medicine

  • Lei Jin Associate Professor (tenured), University of Florida


  • Understand STING functions in humans beyond type I IFNs
  • Review the in vivo mechanism of STING-mediated CD4 T cell death
  • Discuss precision medicine to improve the safety and effectiveness of STING-targeting cancer therapy

12:00 pm Lunch

1:00 pm TME Modelling & Dose Optimization for Solid Tumor Immunotherapy Development – the TriSalus Translational & Clinical Experience

  • Steven Katz Chief Medical Officer, TriSalus Life Sciences


  • Addressing organ-specific immunosuppressive barriers through strategic MoA selection
  • Reflect on the integration of appropriate delivery strategies to enable therapeutic performance
  • Analyze the selection of immunologic read-outs for early phase clinical trials to enable detection of biologic activity

Uncovering the Current Clinical Landscape & Future Directions of Innate Immune Targeted Therapies

1:30 pm A Phase 1 Dose-Escalation & Expansion Study of Intratumorally Administered Dual STING Agonist (ONM-501) Alone & in Combination With Cemiplimab in Patients With Advanced Solid Tumors & Lymphomas


  • Overcoming challenges of early STING Agonists
  • Review the development and mechanism of action of dual STING agonist ONM-501
  • Examine phase 1 trial design and review of trial updates and safety

2:00 pm TAC-001: A Toll-like 9 Receptor Agonist Antibody Conjugate for Solid Tumors


  • Understanding the scientific rationale behind TAC-001, a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22
  • Outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors
  • Exploring the potential of Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates 

2:30 pm Afternoon Break & Poster Presentation Setting


This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of STING/TLR experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.

Exploring Novel Innate Immune System Targets Beyond STING & TLR

3:30 pm Inhibition of METTL3 Activates Innate Immunity Pathways & Reshapes the Tumor Microenvironment


  • STC-15 is a potent and selective inhibitor of the RNA methyltransferase METTL3, currently evaluated in a First-in-Human Phase I clinical trial
  • STC-15 leads to formation of dsRNA and induces cancer intrinsic type-I interferon response
  • Ex-vivo and in-vivo efficacy studies in preclinical models demonstrate an immune based MoA leading to a long term tumour regression and generating durable immune memory

4:00 pm PTPN2/N1 Small Molecule Inhibitor, ABBV-CLS-484, Promotes Activation Of Innate Immune Cell Subsets & Enhances The Inflammatory Phenotype Of Immune Cells In Tumor-Bearing Mice


  • PTPN2/N1 inhibition enhances macrophage and dendritic cell function in response to inflammatory signals
  • Natural killer cell activation and cytotoxic function upon stimulation is enhanced by PTPN2/N1 inhibition
  • Innate immune activation following PTPN2/N1 inhibition correlates with anti-tumor efficacy in mice

4:30 pm Chairs Closing Remarks

4:35 pm
Workshop A: Optimizing Biomarker Use in Innate Immune System Targeted Therapies to Streamline Patient Stratification & Response Assessment Within Clinical Trials

  • Diwakar Davar Associate Professor and Director - Melanoma Clinical and Skin Cancer Program, University of Pittsburgh Medical Center


This workshop aims to delve into the critically useful role of biomarkers in therapies targeting the innate immune system, specifically focusing on STING & TLR receptors. Attendees will gain insights into utilizing biomarkers for patient stratification, assessing treatment response, and addressing the evolving landscape of biomarker integration into clinical practice for optimizing the effectiveness of these therapies.

Biomarker-Driven Patient Stratification Strategies

  • Utilizing biomarkers to categorize patient subgroups for precision treatment
  • Integrating multi-omics data and computational approaches in stratification
  • Reviewing case studies highlighting successful patient stratification in innate immune system therapies

Evaluating Treatment Response via Biomarker Analysis

  • Biomarker-driven assessment of treatment efficacy and response in clinical settings
  • Discussing advancements in imaging, liquid biopsy, and molecular techniques for response monitoring
  • Overcoming challenges and limitations in interpreting biomarker-driven treatment response

Future Perspectives: Emerging Biomarkers & Integration into Clinical Practice

  • Exploring novel biomarkers and technologies for refining patient stratification and response evaluation
  • Gaining insight into regulatory considerations and standardization for biomarker incorporation in clinical trials
  • The road ahead: Integrating biomarkers into routine clinical practice for innate immune system therapies

More speakers to be announced!

6:35 pm End of Day One